TAK-700 (Orteronel) is primarily used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It functions as a selective inhibitor of 17,20-lyase, an enzyme involved in androgen biosynthesis. By blocking this enzyme, TAK-700 reduces the production of androgens such as testosterone and dihydrotestosterone, both of which can fuel the growth of prostate cancer cells. The compound has been investigated in clinical trials to evaluate its efficacy in improving overall survival and delaying disease progression, especially in patients who have not responded to traditional hormone therapies. It is often administered in combination with glucocorticoids to mitigate potential adrenal suppression and related side effects. Due to its targeted mechanism, TAK-700 offers a more specific approach compared to older anti-androgen therapies, potentially resulting in fewer off-target effects. While development and regulatory approval pathways have faced challenges, the compound remains significant in the ongoing effort to develop more effective hormonal therapies for advanced prostate cancer.